In this article from Dr. Anton Iliuk et al., you’ll learn about the viability of monitoring cancer biomarkers with plasma EV phosphoproteomics and chemical affinity purification.

Abstract Summary

Traditional biopsies are invasive and painful for patients undergoing cancer diagnosis and treatment. But analyzing the extracellular vesicles (EVs) in their biofluids is a viable, non-invasive method for monitoring the progression of disease.

In Tymora’s May 2020 publication, Dr. Iliuk and his team explain how they analyze plasma samples: with “a rapid EV isolation method based on chemical affinity called EVtrap.” They offer EVtrap as a service to other researchers, who can collaborate with Tymora to decipher signaling molecules from infected cells.

You can read the article by clicking the button below.

With plasma EVtrap analysis, you can:

• Achieve substantially higher recovery levels compared with ultracentrifugation.
• Distinguish disease states from healthy control in patients’ plasma samples.
• Identify more than 5500 unique phosphopeptides (representing almost 1600 phosphoproteins) with just 1 mL of plasma.
• Help doctors provide patients with a non-invasive (and less painful) option for biopsy procedures.

Want to study plasma proteomics and disease? Our analysis-based services can help.